Aplidine is a new marine-derived anti-cancer chemical entity identified from the Mediterranean tunicate Aplidium albicans. Aplidine is a cyclic depsipeptide (Figure 1 ) structurally related to other naturally occurring didemnins. In contrast to the present candidate, those compounds are only found in various species of a Caribbean tunicate genus, Trididemnin (Sakai et al, 1996) . Aplidine shows potent in vitro activity against human tumour solid cell lines, especially non-small-cell lung and colon tumour cells with IC50 values at 0.18 nM and 0.45 nm respectively (Faircloth et al, 1995; Lobo et al, 1997) . The National Cancer Institute's (NCI) human in vitro panel has confirmed selectivity for non-small-cell lung cancer (NSCLC), melanoma, ovarian and colorectal cancer cell lines .
Initial studies with this marine depsipeptide suggested in vivo activity against murine tumours such as B116 melanoma (Faircloth et al, 1995) . Moreover, additional in vivo studies performed in mice bearing human xenografted tumours confirm activity against breast MX-1 and colon CX-1 . The didemnins exert their anti-tumour effect by interfering with protein synthesis via GTP-dependent inhibition of the elongation factor 1-alpha, a protein translation component (Crews et al, 1994) . Aplidine induces, in vitro and in vivo, a total inhibition of omithine decarboxylase activity at very low concentrations (10-10 M) (Urdiales et al, 1996) . However, the importance of this finding has to be investigated further to understand whether this biochemical effect might be of relevance as a therapeutic intervention (Auvinen, 1997) . A recent in vitro study indicates that the cytotoxicity of aplidine might also be related to the intracellular overaccumulation of spermidine and spermine (Gomez-Fabre et al, 1997 ). An ongoing study is currently addressing the elucidation of additional cellular protein receptors as targets for the didemnins. Preliminary data have identified palmitoyl thioesterase as a binding protein for aplidine and the biological consequences of the interaction with this lysosomal enzyme are under investigation (Crews et al, 1996) .
The present study evaluates the in vitro antiproliferative effect of aplidine in human tumours explanted from patients and human bone marrow.
MATERIAL AND METHODS Compounds
Aplidine was provided by Pharma Mar, Tres Cantos, Madrid, Spain, as a white powder with a chromatographic purity of 98.50% (HPLC assay). The source of the compound was semisynthetic, being synthetized in three steps from natural didemnin A (Rinehart et al, 1991) . 'H nuclear magnetic resonance (NMR) and fast atom bombardment mass spectroscopy (FABMS) spectra of the synthetic compound were identical in all aspects with natural aplidine. Stock solutions and final solutions of aplidine were prepared in dimethyl sulphoxide (DMSO, Serva, Heidelberg, Germany). Doxorubicin was purchased from Farmitalia Carlo Erba, Freiburg, Germany. the laboratory. Preservative-free heparin (10 U ml-', Novo Nordisk, Mainz, Germany) was added immediately after collection of fluids to prevent coagulation. Solid specimens were minced and repeatedly passed through metal meshes with mesh widths of 100 gm and 50 ,um (Linker, Kassel, Germany) to obtain a singlecell suspension. Effusions were centrifuged at 112 g for 5-7 min and passed through 25-g needles to obtain single cell suspensions when necessary. Cells were cryopreserved in culture medium containing 10% DMSO by freezing at a rate of-2°C min-' down to -175°C and stored in liquid nitrogen. Before experiments, the cells were thawed and the DMSO removed. The capillary soft-agar cloning system was used as described previously (Maurer and Ali-Osman, 1981; Hanauske et al, 1985; Von Hoff et al, 1986) . Briefly, cells from tumour specimens were seeded at a median density of 2.3 x 104 cells per capillary (range 1.5 x 104-6.3 x 104 cells per capillary) in 100-jl glass capillaries (Brand, Wertheim, Germany) in a mixture of 0.3% agar (Sigma, Deisenhofen, Germany) in double-enriched Connaught Medical Research Laboratories' (CMRL) Medium 1066 (Gibco) containing 15% horse serum (Gibco), 2% fetal calf serum, 0.3 mmol 1-' vitamin C (Sigma), 90 U ml-' penicillin, 90 jg ml-' streptomycin, 10 mmol 1-1 Hepes, 2 mmol 1-1 sodium pyruvate, 0.1 mmol 1-' non-essential amino acids (Gibco), 4 mmol 1-' glutamine (Gibco), 100 jg ml-' asparagine (Gibco), 4 ng ml-' hydrocortisone (Sigma), 50 U ml-' catalase (Serva) and 0.1 nmol 1-' epidermal growth factor (Flow, Meckenheim, Germany).
For each data point, six capillary tubes were used. Each experiment contained one set of controls with 0.1% DMSO as solvent and a second set with 1 mmol 1-' ammonium monovanadate (Merck, Darmstadt, Germany) , to ensure the presence of a good single-cell suspension (Hanauske et al, 1987) . The colony formation was evaluated with an inverted microscope after an incubation period of 21-28 days at 37°C, 5% carbon dioxide and 100% humidity. Colony formation was considered adequate when the DMSO control had a mean of at least 18 colonies per six capillaries and the vanadate control showed < 30% colony formation compared with DMSO. Tumour specimens were considered to be sensitive if clonogenic growth was < 0.5 x control.
Effects on clonogenic haematopoietic stem cells Cells from frozen peripheral stem cell harvests were thawed and seeded at a density of 105 cells per plate in Petri dishes (Nunc, Naperville, IL, USA) in MethoCult H4431 medium (StemCell Technologies, Vancouver, Canada) containing 10% fetal calf serum and 1 % glutamine. Colony-forming units were evaluated with an inverted microscope after an incubation period of 10-14 days at 37°C, 5% carbon dioxide and 100% humidity and were classified as CFU-GEMM, CFU-GM, BFU-E and cluster (Bradley et al, 1968) . Final concentrations of aplidine were 0.0001-0.1 .tmol 1-'. Doxorubicin was tested at concentrations of 1.0-, 0.1-and 0.01-fold the relevant clinical peak plasma concentrations The experimental design is summarized in Figure 2 .
RESULTS
A total of 56 tumours were included in this experiment. Forty-nine specimens (88%) showed adequate growth in controls using short-term exposure schedules and 54 specimens (96%) showed adequate growth in controls using long-term exposure schedules. The tumour types tested were mainly breast carcinoma, melanoma, ovarian carcinoma, lung carcinoma, colorectal carcinoma, gastric carcinoma and lymphoma. As shown in Table 1 and Figure 3 for the short-term exposure, aplidine has a profound inhibitory effect on tumour colony formation. The anti-tumour effect is concentration dependent. At 0.01 ,umol 1-1, in vitro growth of 17/49 (35%) evaluable specimens was inhibited; at 0.05,mol 1-', 40/49 (82%) specimens were inhibited; and at concentrations > 0.5 ,tmol 1-', colony formation of 49/49 (100%) tumours was inhibited.
The comparison of median reductions of colony formation also demonstrates that aplidine is active at > 0.01 ,umol 1-1. Moreover, ovarian, lymphoma and colorectal cancer specimens appear to be selectively sensitive to the lowest concentration, 0.01 g.mol 1-l? tested in a short-term exposure schedule.
For continuous exposure experiments, concentrations ranged from 0.0001 tmol 1-' to 1.0 tmol 1-'. Again, the data show a concentration-dependent anti-tumour activity ( Figure 4 , Table 2 ).
The lowest active concentration evaluated, 0.001 tmol 1-', suggests that non-small-cell lung cancer, melanoma, and breast cancer might be highly sensitive to this compound at long-term exposure.
The indication that a better activity profile is achievable by using a continuous exposure schedule led to prospective head to head comparisons of short-term vs long-term drug exposures. As shown in Figure 5A -C, the inhibition of tumour-forming units was more pronounced with the long-term exposure. This argues for a schedule-dependent activity of aplidine in vitro.
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0.05 imol 1-} for short-term exposure (CFU-GEMM, CFU-GM, BFU-E and cluster). At this concentration, 82% of tumour specimens are inhibited (colony growth < 0.5 x control), with high in vitro activity against breast, melanoma, ovarian, colon, lymphoma and non-small-cell lung cancer. In addition, tumour inhibition at subtoxic concentrations, 0.01 ltM, is observed in ovarian and colon cancer and lymphoma. Concentrations in the range of 0.02-0.03 ,umol 1-' showed similar toxicity to doxorubicin at clinically relevant concentrations. For the long-term exposure, the IC50 of aplidine is 0.01 gmol 1-(CFU-GM and BFU-E). At this concentration, between 50% and 94% of the tumours are inhibited (colony growth < 0.5 x control). Moreover, marginally myelotoxic concentrations of aplidine, 0.001 gM, yielded to tumour inhibition in breast, melanoma and non-small-cell lung cancer.
DISCUSSION
Aplidine is a new marine-derived anti-cancer candidate structurally related to didemnin B, the first marine anti-cancer compound to enter clinical trials (Chun et al, 1986) . In fact, didemnin B was the subject of a large phase I/II programme sponsored by the US National Cancer Institute (Bethesda, MD, USA). Initial phase I trials were performed in the early 1980s, but dose escalation was hampered by the onset of severe emesis (Doff et al, 1988; Stewart et al, 1991) . As a result, subsequent phase II studies included suboptimal dose levels, but minor responses were observed in non-small-cell lung cancer and prostatic cancer. Later, a new dose escalation programme with aggressive antiemetic protection was implemented and determined a new maximum tolerable dose and also of new dose-limiting toxicities, specifically cardiac and neuromuscular (Shin et al, 1991) . A number of phase II studies incorporating a higher optimal dose were conducted, and positive results in heavily treated patients with low-grade nonHodgkin's lymphoma (NHL) have recently been presented (Kucuk et al, 1996) . The overall data from the phase II programme with didemnin B indicate that repeated cycles of therapy are hampered by acute cardiotoxicity and neurotoxicity. However, the innovative features of the didemnin family as potential anti-cancer entities led to the establishment of a discovery programme searching for active derivatives with differential toxicities and better therapeutic indexes (Faircloth et al, 1995) . Aplidine has been identified as a new generation didemnin that harbours interesting differential patterns in terms of the mechanism of action, potency and toxicological profile . An in vitro study assessing the cardiotoxic potential of aplidine confirms a lack of cardiotoxic effect at active concentrations (Faircloth et al, 1995) . In this experiment, the parent compound, didemnin B, shows clear evidence of cardiotoxicity at anti-tumour in vitro concentrations. Moreover, early data from an in vitro study comparing the neurotoxic potential of aplidine and didemnin B, in a murine clonal phaeochromocytoma cell line PC 12 (Geldof, 1995) , indicate a better therapeutic index for aplidine and confirm the possibility of inducing a marked anti-tumour effect at nonneurotoxic concentrations.
The present report uses an in vitro cloning system with freshly explanted human tumours and clearly shows a concentrationdependent anti-tumour activity. Interestingly, the current work indicates that a better anti-tumour effect is achieved when tumour cells are continuously exposed to the study drug. Moreover, it appears that tumour types such as colon cancer, non-small-cell lung cancer, melanoma, breast and ovarian cancer and lymphomas might be a target for further development. Recent in vivo data confirm activity against human Burkitt's lymphoma and prostatic PC3 androgen-independent tumour models. In addition, the pattern of tumour inhibition is consistent with a cytostatic effect, supporting a time of exposure-activity relationship in the in vivo setting (Faircloth et al, 1997) .
In addition, evaluation of the myelotoxic potential of aplidine has been the subject of the present investigation. Its in vitro haematotoxicity is both affected by concentration and time of exposure. This part of our study suggests the feasibility of improving its therapeutic index by continuous exposure of aplidine, with concentrations of 0.001 tM inducing anti-tumour effects but mild toxicity in bone marrow progenitors. Of note is the observation that myelotoxicity has been a rare event in phase II studies with didemnin B, even at optimal dose levels (Malfetano et al, 1993 (Malfetano et al, , 1996 Kucuk et al, 1996) .
In summary, the current in vitro investigation identifies a number of tumour types that are sensitive to low concentrations of aplidine. The magnitude of its anti-tumour effect is dependent on the time of exposure and seems to be achievable at non-myelotoxic concentrations. Aplidine is under late preclinical development, and phase I trials incorporating prolonged/protracted infusions are planned.
